X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs PANACEA BIOTECH - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS PANACEA BIOTECH NOVARTIS/
PANACEA BIOTECH
 
P/E (TTM) x 363.5 170.2 213.6% View Chart
P/BV x 17.9 3.8 473.3% View Chart
Dividend Yield % 1.6 0.0 -  

Financials

 NOVARTIS   PANACEA BIOTECH
EQUITY SHARE DATA
    NOVARTIS
Mar-16
PANACEA BIOTECH
Mar-14
NOVARTIS/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs982149 660.4%   
Low Rs55682 675.8%   
Sales per share (Unadj.) Rs252.984.1 300.6%  
Earnings per share (Unadj.) Rs62.1-18.3 -339.5%  
Cash flow per share (Unadj.) Rs63.3-6.7 -944.8%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs363.683.7 434.4%  
Shares outstanding (eoy) m31.9661.25 52.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.01.4 221.5%   
Avg P/E ratio x12.4-6.3 -196.2%  
P/CF ratio (eoy) x12.2-17.2 -70.5%  
Price / Book Value ratio x2.11.4 153.3%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m24,5807,074 347.5%   
No. of employees `0000.82.8 27.3%   
Total wages/salary Rs m1,8011,449 124.3%   
Avg. sales/employee Rs Th10,748.91,874.1 573.6%   
Avg. wages/employee Rs Th2,395.2527.0 454.5%   
Avg. net profit/employee Rs Th2,641.1-407.7 -647.7%   
INCOME DATA
Net Sales Rs m8,0835,154 156.8%  
Other income Rs m829100 831.1%   
Total revenues Rs m8,9135,254 169.7%   
Gross profit Rs m234-766 -30.6%  
Depreciation Rs m37711 5.2%   
Interest Rs m21,503 0.1%   
Profit before tax Rs m1,025-2,881 -35.6%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m17-6 -293.0%   
Extraordinary Inc (Exp) Rs m1,6961,771 95.8%   
Tax Rs m75217 4,476.2%   
Profit after tax Rs m1,986-1,121 -177.1%  
Gross profit margin %2.9-14.9 -19.5%  
Effective tax rate %73.4-0.6 -12,578.0%   
Net profit margin %24.6-21.8 -112.9%  
BALANCE SHEET DATA
Current assets Rs m12,6783,810 332.7%   
Current liabilities Rs m2,4338,365 29.1%   
Net working cap to sales %126.7-88.4 -143.4%  
Current ratio x5.20.5 1,144.0%  
Inventory Days Days33156 21.0%  
Debtors Days Days2267 33.4%  
Net fixed assets Rs m6914,480 0.5%   
Share capital Rs m16061 260.7%   
"Free" reserves Rs m11,460903 1,269.0%   
Net worth Rs m11,6215,127 226.7%   
Long term debt Rs m05,832 0.0%   
Total assets Rs m14,40019,433 74.1%  
Interest coverage x570.5-0.9 -62,247.7%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.60.3 211.7%   
Return on assets %13.82.0 702.9%  
Return on equity %17.1-21.9 -78.1%  
Return on capital %23.63.6 648.4%  
Exports to sales %0.724.5 3.0%   
Imports to sales %18.610.2 182.6%   
Exports (fob) Rs m601,264 4.8%   
Imports (cif) Rs m1,503525 286.3%   
Fx inflow Rs m1861,539 12.1%   
Fx outflow Rs m1,821942 193.3%   
Net fx Rs m-1,635597 -273.7%   
CASH FLOW
From Operations Rs m2,531599 422.4%  
From Investments Rs m-8,270-438 1,888.5%  
From Financial Activity Rs m-386-303 127.5%  
Net Cashflow Rs m-6,125-141 4,334.4%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 0.6 333.3%  
FIIs % 1.6 1.3 123.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 23.6 91.1%  
Shareholders   41,647 10,259 406.0%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  AJANTA PHARMA  UNICHEM LAB  

Compare NOVARTIS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Down Around 1%; Telecom & Metal Stocks Decline(01:30 pm)

Indian share markets are trading in the red presently. Sectoral indices are trading in the red with stocks in the telecom sector and metal sector witnessing maximum selling pressure.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 19, 2018 01:59 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - PIRAMAL ENTERPRISES COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS